- Home
- LQDA vs NG Comparison
LQDA vs NG Comparison
Compare LQDA & NG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LQDA
- NG
- Stock Information
- Founded
- LQDA 2004
- NG 1984
- Country
- LQDA United States
- NG Canada
- Employees
- LQDA N/A
- NG N/A
- Industry
- LQDA Biotechnology: Pharmaceutical Preparations
- NG Precious Metals
- Sector
- LQDA Health Care
- NG Basic Materials
- Exchange
- LQDA Nasdaq
- NG Nasdaq
- Market Cap
- LQDA 1.9B
- NG 1.5B
- IPO Year
- LQDA 2018
- NG N/A
- Fundamental
- Price
- LQDA $23.15
- NG $8.19
- Analyst Decision
- LQDA Strong Buy
- NG Strong Buy
- Analyst Count
- LQDA 9
- NG 3
- Target Price
- LQDA $32.67
- NG $10.17
- AVG Volume (30 Days)
- LQDA 2.1M
- NG 4.7M
- Earning Date
- LQDA 11-03-2025
- NG 10-01-2025
- Dividend Yield
- LQDA N/A
- NG N/A
- EPS Growth
- LQDA N/A
- NG N/A
- EPS
- LQDA N/A
- NG N/A
- Revenue
- LQDA $19,322,000.00
- NG N/A
- Revenue This Year
- LQDA $424.31
- NG N/A
- Revenue Next Year
- LQDA $359.32
- NG N/A
- P/E Ratio
- LQDA N/A
- NG N/A
- Revenue Growth
- LQDA 30.20
- NG N/A
- 52 Week Low
- LQDA $9.71
- NG $2.26
- 52 Week High
- LQDA $29.94
- NG $10.90
- Technical
- Relative Strength Index (RSI)
- LQDA 48.99
- NG 45.80
- Support Level
- LQDA $21.97
- NG $7.67
- Resistance Level
- LQDA $24.34
- NG $8.91
- Average True Range (ATR)
- LQDA 1.20
- NG 0.51
- MACD
- LQDA 0.05
- NG -0.30
- Stochastic Oscillator
- LQDA 40.98
- NG 16.87
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
About NG Novagold Resources Inc.
Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other presious metals.